PANTHERx pioneered the rare pharmacy ... the rare disease community. Through deep therapy expertise, meaningful relationships, and a commitment to removing barriers to care, PANTHERx helps patients access and stay on therapy while delivering the high-touch support, reliability, and collaboration that patients and partners depend on. "PANTHERx was built to help patients navigate complex rare therapy journeys with urgency and precision. We are grateful for the partnership and support ... PANTHERx pioneered the rare pharmacy model and serves as a trusted partner across the rare disease community. Through deep therapy expertise, meaningful relationships, and a commitment to removing barriers to care, PANTHERx helps patients access and stay on therapy while delivering the high-touch support, reliability, and collaboration that patients and partners depend on. "PANTHERx was built to help patients navigate complex rare therapy journeys with urgency and precision. We are grateful for the partnership and support from Nautic Partners, General Atlantic, and The Vistria Group, whose investment helped expand our impact for patients and shape the company we are today," said Bansi Nagji, Chief Executive Officer of PANTHERx. The firm employs a proactive, thematic investment strategy and partners with strong management teams to accelerate the growth of its portfolio companies through strategic add-on acquisitions, targeted operational initiatives, and deep sector expertise. For more information, please visit www.nautic.com. About PANTHERx Rare PANTHERx Rare makes rare disease care more hyper-personalized and less overwhelming by focusing relentlessly on each patient and each therapy. "We are excited to begin this next chapter with Warburg Pincus and Nautic Partners. This partnership reinforces our position as an independent, rare-focused pharmacy and supports continued investment in people, capabilities, and technology to help us serve more rare disease patients with the expertise and compassion that define PANTHERx." "The Company combines deep clinical specialization, high-touch service, and strong manufacturer partnerships. We look forward to partnering with Bansi and the PANTHERx team to support the Company's continued growth and expand access to life-changing therapies for patients with rare diseases across the United States," added Adam Krainson, Managing Director, Warburg Pincus.

Original title: “Warburg Pincus-Led Investor Group Agrees to Acquire Controlling Interest in PANTHERx® Rare - BioSpace”

The new study results could make Abbott, which has an agreement with Freenome to market the blood-based test, the dominant player in colorectal cancer screening, Evercore ISI analysts said.

Original title: “Freenome colorectal cancer test data improve on earlier results”

The trials, which were testing the tyrosine kinase inhibitor masitinib, had previously been paused. AB Science’s decision not to resume them was a matter of prioritization, not safety, the biotech said.

Original title: “AB Science ends 3 studies in multiple sclerosis, other immune conditions”

Though funding totals represented the highest first-half sum since the start of 2022, industry watchers are concerned that small startups are being left behind.

Original title: “Biotech startup funding gap widens despite rebound in VC investment”

GSK and Hansoh Pharmaceutical’s antibody-drug conjugate success validates their partnership, one of the many deals in which Big Pharma has tapped a China company for promising cancer candidates.

Original title: “GSK and Hansoh’s ADC clinches late-stage win, teeing up regulatory submission in China”

The failure of AstraZeneca and Ionis’ Wainua in a late-stage study of ATTR-CM casts doubt on Alnylam’s next-generation candidate but is good news for others in the space, including BridgeBio and Intellia Therapeutics.

Original title: “AstraZeneca, Ionis’ Wainua woes send waves across ATTR-CM space”